We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current MEPDF market cap is 3.43B. The company's latest EPS is JPY 187.4181 and P/E is 0.08.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 3.25T | 3.21T | 3.29T | 3.36T | 3.56T |
| Operating Income | 55.25B | 39.79B | 49.01B | 52.31B | 49.64B |
| Net Income | 37.97B | 23.93B | 29.42B | 38.81B | 41.47B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 1.64T | 1.68T | 1.71T | 1.7T | 1.8T |
| Total Liabilities | 1.04T | 1.04T | 1.06T | 1.02T | 1.06T |
| Total Equity | 607.43B | 638.93B | 649.09B | 688.06B | 736.61B |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 56.92B | 34.45B | 61.22B | 16.15B | 61.84B |
| Investing | -13.32B | -2.94B | -24.34B | -39.49B | -7.82B |
| Financing | -49.07B | -16B | -16.47B | -43.54B | -25.25B |
| Market Cap | 3.43B |
| Price to Earnings Ratio | 0.08 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.01 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 221.29M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -3.13% |
| 52 Week High | 17.067 |
| 52 Week Low | 15.51 |
| Spread (Intraday) | 1.49 (9.88%) |
| Company Name | Medipal Holdings Corporation (PK) |
| Address |
3-1-1 kyobashi chuo, tokyo 104-8461 |
| Website | https://www.medipal.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
